111 related articles for article (PubMed ID: 22488744)
1. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer.
Weickhardt AJ; Rothman MS; Salian-Mehta S; Kiseljak-Vassiliades K; Oton AB; Doebele RC; Wierman ME; Camidge DR
Cancer; 2012 Nov; 118(21):5302-9. PubMed ID: 22488744
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients.
Weickhardt AJ; Doebele RC; Purcell WT; Bunn PA; Oton AB; Rothman MS; Wierman ME; Mok T; Popat S; Bauman J; Nieva J; Novello S; Ou SH; Camidge DR
Cancer; 2013 Jul; 119(13):2383-90. PubMed ID: 23585220
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib: a new treatment option for ALK-positive non-small cell lung cancer.
O'Bryant CL; Wenger SD; Kim M; Thompson LA
Ann Pharmacother; 2013 Feb; 47(2):189-97. PubMed ID: 23386065
[TBL] [Abstract][Full Text] [Related]
4. Hypogonadism related to crizotinib therapy: implications for patient care.
Ramalingam SS; Shaw AT
Cancer; 2012 Nov; 118(21):E1-2. PubMed ID: 22487894
[No Abstract] [Full Text] [Related]
5. Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases.
Rodig SJ; Shapiro GI
Curr Opin Investig Drugs; 2010 Dec; 11(12):1477-90. PubMed ID: 21154129
[TBL] [Abstract][Full Text] [Related]
6. ALK translocation and crizotinib in non-small cell lung cancer: an evolving paradigm in oncology drug development.
Scagliotti G; Stahel RA; Rosell R; Thatcher N; Soria JC
Eur J Cancer; 2012 May; 48(7):961-73. PubMed ID: 22397764
[TBL] [Abstract][Full Text] [Related]
7. Heart rate decrease during crizotinib treatment and potential correlation to clinical response.
Ou SH; Tong WP; Azada M; Siwak-Tapp C; Dy J; Stiber JA
Cancer; 2013 Jun; 119(11):1969-75. PubMed ID: 23505007
[TBL] [Abstract][Full Text] [Related]
8. Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer.
Sargis RM; Salgia R
Am J Clin Oncol; 2015 Oct; 38(5):442-7. PubMed ID: 23934135
[TBL] [Abstract][Full Text] [Related]
9. Acute kidney injury following crizotinib administration for non-small-cell lung carcinoma.
Gastaud L; Ambrosetti D; Otto J; Marquette CH; Coutts M; Hofman P; Esnault V; Favre G
Lung Cancer; 2013 Nov; 82(2):362-4. PubMed ID: 24001942
[TBL] [Abstract][Full Text] [Related]
10. Successful desensitization of two patients with ALK-positive lung cancer and hypersensitivity to crizotinib.
Awad MM; Lax TP; Slawski BR; Shaw AT
J Thorac Oncol; 2014 Nov; 9(11):1726-8. PubMed ID: 25436807
[TBL] [Abstract][Full Text] [Related]
11. Treatment of ALK-positive non-small cell lung cancer.
Bang YJ
Arch Pathol Lab Med; 2012 Oct; 136(10):1201-4. PubMed ID: 23020724
[TBL] [Abstract][Full Text] [Related]
12. Crizotinib-induced cardiotoxicity: the importance of a proactive monitoring and management.
Tartarone A; Gallucci G; Lazzari C; Lerose R; Lombardi L; Aieta M
Future Oncol; 2015; 11(14):2043-8. PubMed ID: 26198834
[TBL] [Abstract][Full Text] [Related]
13. Crizotinib-associated erythema multiforme in a lung cancer patient.
Sawamura S; Kajihara I; Ichihara A; Fukushima S; Jinnin M; Yamaguchi E; Kohrogi H; Ihn H
Drug Discov Ther; 2015 Apr; 9(2):142-3. PubMed ID: 25994067
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib.
Prescrire Int; 2013 Nov; 22(143):264. PubMed ID: 24427836
[TBL] [Abstract][Full Text] [Related]
15. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
Ou SH
Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
[TBL] [Abstract][Full Text] [Related]
16. Severe acute interstitial lung disease after crizotinib therapy in a patient with EML4-ALK-positive non-small-cell lung cancer.
Tamiya A; Okamoto I; Miyazaki M; Shimizu S; Kitaichi M; Nakagawa K
J Clin Oncol; 2013 Jan; 31(1):e15-7. PubMed ID: 23169500
[No Abstract] [Full Text] [Related]
17. Crizotinib-induced fatal fulminant liver failure.
van Geel RM; Hendrikx JJ; Vahl JE; van Leerdam ME; van den Broek D; Huitema AD; Beijnen JH; Schellens JH; Burgers SA
Lung Cancer; 2016 Mar; 93():17-9. PubMed ID: 26898609
[TBL] [Abstract][Full Text] [Related]
18. Factors associated with sinus bradycardia during crizotinib treatment: a retrospective analysis of two large-scale multinational trials (PROFILE 1005 and 1007).
Ou SH; Tang Y; Polli A; Wilner KD; Schnell P
Cancer Med; 2016 Apr; 5(4):617-22. PubMed ID: 26823131
[TBL] [Abstract][Full Text] [Related]
19. Successful crizotinib rechallenge after crizotinib-induced interstitial lung disease.
Tachihara M; Kobayashi K; Ishikawa Y; Hori S; Tamura D; Otera H; Funada Y; Nishimura Y
Jpn J Clin Oncol; 2014 Aug; 44(8):762-4. PubMed ID: 24872405
[TBL] [Abstract][Full Text] [Related]
20. Complex renal cysts associated with crizotinib treatment.
Schnell P; Bartlett CH; Solomon BJ; Tassell V; Shaw AT; de Pas T; Lee SH; Lee GK; Tanaka K; Tan W; Tang Y; Wilner KD; Safferman A; Han JY
Cancer Med; 2015 Jun; 4(6):887-96. PubMed ID: 25756473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
